To The Moon

This year marks my first trading journey. First of all, thanks to the Tiger team for making this platform user-friendly even for a newbie like me. I started with small investments in reputable tech stocks like Nvidia, Google, Apple and Microsoft. It all played out well till the market crashed in August. I have learnt so much in this year including utilizing call and put options such as selling covered calls when the market is volatile and earning some incomes while holding my favorite stocks. The 2024 market has been a rollercoaster due to the US election and uncertainty in the economics. Now, things have settled down. I am expecting 2025 to be a great year for investors and traders. The stocks related to AI and Nuclear Energy should be in everyone's bookmarks. Long story short,

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.Tonix Pharmaceuticals Holding Corp. is on a mission to bring a better drug for fibromyalgia to the market, which is estimated to grow to a value of $4.13 billion globally in 2032 from $2.8 billion in 2024. The biopharmaceutical company submitted a new drug application to the U.S. Food and Drug Administration in October for TNX-102 SL , Tonix's drug candidate for the management of fibromyalgia."The Fast Track designation underscores the importance of addressing the unmet needs of fibromyalgia patients," said Seth Lederman, M.D., Chief Executive Officer of